Industry analysts point to a shift toward more sophisticated, controlled environments as the primary driver for this valuation increase. While traditional manual workflows remain active, pharmaceutical and biotechnology firms are increasingly adopting serum-free media, chemically defined formulations, and single-use bioreactors. These technologies are critical for improving process consistency and scalability in the production of biologics and biosimilars.

Consumables continue to dominate the landscape, accounting for 73.9% of the market share in 2025 due to the high frequency of purchases for media, reagents, and specialized vessels. Meanwhile, the sector for tissue engineering and regenerative medicine is expected to experience the fastest growth, with a projected CAGR of 13.9%. North America maintains its position as the leading market, supported by an established infrastructure of clinical trial networks, government-funded research, and a dense concentration of major industry players such as Thermo Fisher Scientific, Danaher, and Sartorius AG.